Top

Journal of Assisted Reproduction and Genetics

Published in:

01-09-2017 | Fertility Preservation

Medical and elective fertility preservation: impact of removal of the experimental label from oocyte cryopreservation

Authors: Samantha B. Schon, Maren Shapiro, Clarisa Gracia, Suneeta Senapati

Published in: Journal of Assisted Reproduction and Genetics | Issue 9/2017

Abstract

Purpose

The purpose of this study was to compare baseline characteristics and ovarian stimulation outcomes between patients presenting for medically indicated vs. elective fertility preservation consultation and to determine the impact of the 2013 ASRM guidelines on oocyte cryopreservation on the patient population presenting for fertility preservation consultation.

Methods

Retrospective cohort study conducted at an academic center. Study population included 332 patients presenting for medically indicated fertility preservation consultation and 210 patients presenting for elective consultation.

Results

Patients presenting for elective fertility preservation consultation were more likely to be of advanced age, non-Caucasian, highly educated, single, nulligravid, and meet criteria for diminished ovarian reserve (DOR). Additionally, patients presenting electively were more likely to have fertility insurance benefits. A higher percentage of patients with insurance benefits for oocyte cryopreservation proceeded to stimulation. There were no differences in stimulation parameters or number of retrieved oocytes between the groups when adjusted for age. Following release of the ASRM guidelines on oocyte cryopreservation, there was no difference in the percentage of patients in the medical group who proceeded with stimulation; however, a higher percentage of patients presenting electively underwent ovarian stimulation.

Conclusion

Although the populations presenting for medical compared with elective fertility preservation differ at baseline, ovarian stimulation parameters and outcomes are similar when adjusted for age. Insurance benefits for fertility preservation are not comprehensive and impact the decision to proceed with stimulation in all patients. The publication of the ASRM guidelines on oocyte cryopreservation increased utilization of this technology among patients presenting electively; however, they remained at an advanced age and with decreased ovarian reserve parameters.

Available only for authorised users

Cil AP, Turkgeldi L, Seli E. Oocyte cryopreservation as a preventive measure for age-related fertility loss. Semin Reprod Med. 2015;33(6):429–35. doi:10.1055/s-0035-1567819.CrossRefPubMed

Rudick B, Opper N, Paulson R, Bendikson K, Chung K. The status of oocyte cryopreservation in the United States. Fertil Steril. 2010;94(7):2642–6. doi:10.1016/j.fertnstert.2010.04.079.CrossRefPubMed

Zoll M, Mertes H, Gupta J. Corporate giants provide fertility benefits: have they got it wrong? Eur J Obstet Gynecol Reprod Biol. 2015;195:A1–2. doi:10.1016/j.ejogrb.2015.10.018.CrossRefPubMed

Mertes H, Pennings G. Social egg freezing: for better, not for worse. Reprod BioMed Online. 2011;23(7):824–9. doi:10.1016/j.rbmo.2011.09.010.CrossRefPubMed

Goldman KN, Grifo JA. Elective oocyte cryopreservation for deferred childbearing. Curr Opin Endocrinol Diabetes Obes. 2016;23(6):458–64. doi:10.1097/MED.0000000000000291.CrossRefPubMed

Daniluk JC, Koert E. Childless women’s beliefs and knowledge about oocyte freezing for social and medical reasons. Hum Reprod. 2016;31(10):2313–20. doi:10.1093/humrep/dew189.CrossRefPubMed

Practice Committees of American Society for Reproductive M, Society for Assisted Reproductive T. Mature oocyte cryopreservation: a guideline. Fertil Steril. 2013;99(1):37–43. doi:10.1016/j.fertnstert.2012.09.028.CrossRef

Ethics ETFo, Law, Dondorp W, de Wert G, Pennings G, Shenfield F, et al. Oocyte cryopreservation for age-related fertility loss. Hum Reprod. 2012;27(5):1231–7. doi:10.1093/humrep/des029.CrossRef

Johnson LN, Dillon KE, Sammel MD, Efymow BL, Mainigi MA, Dokras A, et al. Response to ovarian stimulation in patients facing gonadotoxic therapy. Reprod BioMed Online. 2013;26(4):337–44. doi:10.1016/j.rbmo.2013.01.003.CrossRefPubMedPubMedCentral

10.

Almog B, Azem F, Gordon D, Pauzner D, Amit A, Barkan G, et al. Effects of cancer on ovarian response in controlled ovarian stimulation for fertility preservation. Fertil Steril. 2012;98(4):957–60. doi:10.1016/j.fertnstert.2012.06.007.CrossRefPubMed

11.

Cardozo ER, Thomson AP, Karmon AE, Dickinson KA, Wright DL, Sabatini ME. Ovarian stimulation and in-vitro fertilization outcomes of cancer patients undergoing fertility preservation compared to age matched controls: a 17-year experience. J Assist Reprod Genet. 2015;32(4):587–96. doi:10.1007/s10815-015-0428-z.CrossRefPubMedPubMedCentral

12.

Domingo J, Guillen V, Ayllon Y, Martinez M, Munoz E, Pellicer A, et al. Ovarian response to controlled ovarian hyperstimulation in cancer patients is diminished even before oncological treatment. Fertil Steril. 2012;97(4):930–4. doi:10.1016/j.fertnstert.2012.01.093.CrossRefPubMed

13.

Druckenmiller S, Goldman KN, Labella PA, Fino ME, Bazzocchi A, Noyes N. Successful oocyte cryopreservation in reproductive-aged cancer survivors. Obstet Gynecol. 2016;127(3):474–80. doi:10.1097/AOG.0000000000001248.CrossRefPubMed

14.

Friedler S, Koc O, Gidoni Y, Raziel A, Ron-El R. Ovarian response to stimulation for fertility preservation in women with malignant disease: a systematic review and meta-analysis. Fertil Steril. 2012;97(1):125–33. doi:10.1016/j.fertnstert.2011.10.014.CrossRefPubMed

15.

Knopman JM, Noyes N, Talebian S, Krey LC, Grifo JA, Licciardi F. Women with cancer undergoing ART for fertility preservation: a cohort study of their response to exogenous gonadotropins. Fertil Steril. 2009;91(4 Suppl):1476–8. doi:10.1016/j.fertnstert.2008.07.1727.CrossRefPubMed

16.

Quintero RB, Helmer A, Huang JQ, Westphal LM. Ovarian stimulation for fertility preservation in patients with cancer. Fertil Steril. 2010;93(3):865–8. doi:10.1016/j.fertnstert.2008.10.007.CrossRefPubMed

17.

Baldwin K, Culley L, Hudson N, Mitchell H, Lavery S. Oocyte cryopreservation for social reasons: demographic profile and disposal intentions of UK users. Reprod BioMed Online. 2015;31(2):239–45. doi:10.1016/j.rbmo.2015.04.010.CrossRefPubMed

18.

Hodes-Wertz B, Druckenmiller S, Smith M, Noyes N. What do reproductive-age women who undergo oocyte cryopreservation think about the process as a means to preserve fertility? Fertil Steril. 2013;100(5):1343–9. doi:10.1016/j.fertnstert.2013.07.201.CrossRefPubMed

19.

Tsafrir A, Haimov-Kochman R, Margalioth EJ, Eldar-Geva T, Gal M, Bdolah Y, et al. Ovarian stimulation for oocyte cryopreservation for prevention of age-related fertility loss: one in five is a low responder. Gynecol Endocrinol. 2015;31(10):779–82. doi:10.3109/09513590.2015.1062859.CrossRefPubMed

20.

Doyle JO, Richter KS, Lim J, Stillman RJ, Graham JR, Tucker MJ. Successful elective and medically indicated oocyte vitrification and warming for autologous in vitro fertilization, with predicted birth probabilities for fertility preservation according to number of cryopreserved oocytes and age at retrieval. Fertil Steril. 2016;105(2):459–466 e2. doi:10.1016/j.fertnstert.2015.10.026.CrossRefPubMed

21.

Cobo A, Garcia-Velasco JA, Coello A, Domingo J, Pellicer A, Remohi J. Oocyte vitrification as an efficient option for elective fertility preservation. Fertil Steril. 2016;105(3):755–764 e8. doi:10.1016/j.fertnstert.2015.11.027.CrossRefPubMed

22.

Garcia-Velasco JA, Domingo J, Cobo A, Martinez M, Carmona L, Pellicer A. Five years’ experience using oocyte vitrification to preserve fertility for medical and nonmedical indications. Fertil Steril. 2013;99(7):1994–9. doi:10.1016/j.fertnstert.2013.02.004.CrossRefPubMed

23.

Chan JL, Johnson LN, Efymow BL, Sammel MD, Gracia CR. Outcomes of ovarian stimulation after treatment with chemotherapy. J Assist Reprod Genet. 2015;32(10):1537–45. doi:10.1007/s10815-015-0575-2.CrossRefPubMedPubMedCentral

24.

O'Neill KE, Senapati S, Maina I, Gracia C, Dokras A. GnRH agonist with low-dose hCG (dual trigger) is associated with higher risk of severe ovarian hyperstimulation syndrome compared to GnRH agonist alone. J Assist Reprod Genet. 2016;33(9):1175–84. doi:10.1007/s10815-016-0755-8.CrossRefPubMedPubMedCentral

25.

Practice Committee of the American Society for Reproductive Medicine. Electronic address Aao, Practice Committee of the American Society for Reproductive M. Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. Fertil Steril. 2016;106(7):1634–47. doi:10.1016/j.fertnstert.2016.08.048.CrossRef

26.

Baldwin K, Culley L, Hudson N, Mitchell H. Reproductive technology and the life course: current debates and research in social egg freezing. Hum Fertil (Camb). 2014;17(3):170–9. doi:10.3109/14647273.2014.939723.CrossRef

27.

Kim J, Deal AM, Balthazar U, Kondapalli LA, Gracia C, Mersereau JE. Fertility preservation consultation for women with cancer: are we helping patients make high-quality decisions? Reprod BioMed Online. 2013;27(1):96–103. doi:10.1016/j.rbmo.2013.03.004.CrossRefPubMed

28.

Hill KA, Nadler T, Mandel R, Burlein-Hall S, Librach C, Glass K, et al. Experience of young women diagnosed with breast cancer who undergo fertility preservation consultation. Clin Breast Cancer. 2012;12(2):127–32. doi:10.1016/j.clbc.2012.01.002.CrossRefPubMed

29.

Yee S, Abrol K, McDonald M, Tonelli M, Liu KE. Addressing oncofertility needs: views of female cancer patients in fertility preservation. J Psychosoc Oncol. 2012;30(3):331–46. doi:10.1080/07347332.2012.664257.CrossRefPubMed

30.

Tan SQ, Tan AW, Lau MS, Tan HH, Nadarajah S. Social oocyte freezing: a survey among Singaporean female medical students. J Obstet Gynaecol Res. 2014;40(5):1345–52. doi:10.1111/jog.12347.CrossRefPubMed

31.

Mertes H. Does company-sponsored egg freezing promote or confine women’s reproductive autonomy? J Assist Reprod Genet. 2015;32(8):1205–9. doi:10.1007/s10815-015-0500-8.CrossRefPubMedPubMedCentral

32.

Linkeviciute A, Peccatori FA, Sanchini V, Boniolo G. Oocyte cryopreservation beyond cancer: tools for ethical reflection. J Assist Reprod Genet. 2015;32(8):1211–20. doi:10.1007/s10815-015-0524-0.CrossRefPubMedPubMedCentral

33.

Bavan B, Porzig E, Baker VL. An assessment of female university students’ attitudes toward screening technologies for ovarian reserve. Fertil Steril. 2011;96(5):1195–9. doi:10.1016/j.fertnstert.2011.08.018.CrossRefPubMed

34.

Birch Petersen K, Hvidman HW, Sylvest R, Pinborg A, Larsen EC, Macklon KT, et al. Family intentions and personal considerations on postponing childbearing in childless cohabiting and single women aged 35-43 seeking fertility assessment and counselling. Hum Reprod. 2015;30(11):2563–74. doi:10.1093/humrep/dev237.CrossRefPubMed

35.

Yu L, Peterson B, Inhorn MC, Boehm JK, Patrizio P. Knowledge, attitudes, and intentions toward fertility awareness and oocyte cryopreservation among obstetrics and gynecology resident physicians. Hum Reprod. 2016;31(2):403–11. doi:10.1093/humrep/dev308.PubMed

36.

Stoop D, Maes E, Polyzos NP, Verheyen G, Tournaye H, Nekkebroeck J. Does oocyte banking for anticipated gamete exhaustion influence future relational and reproductive choices? A follow-up of bankers and non-bankers. Hum Reprod. 2015;30(2):338–44. doi:10.1093/humrep/deu317.CrossRefPubMed

37.

Friedman D. Perk up: Facebook and apple now pay for women to freeze eggs. http://www.nbcnews.com/news/us-news/perk-facebook-apple-now-pay-women-freeze-eggs-n225011. 2014.

Title: Medical and elective fertility preservation: impact of removal of the experimental label from oocyte cryopreservation
Authors: Samantha B. Schon
Maren Shapiro
Clarisa Gracia
Suneeta Senapati
Publication date: 01-09-2017
Publisher: Springer US
Published in: Journal of Assisted Reproduction and Genetics / Issue 9/2017
Print ISSN: 1058-0468
Electronic ISSN: 1573-7330
DOI: https://doi.org/10.1007/s10815-017-0968-5

At a glance: The STEP trials

Springer Medicine

Medical and elective fertility preservation: impact of removal of the experimental label from oocyte cryopreservation

Abstract

Purpose

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 9/2017

Age-related expression of TGF beta family receptors in human cumulus oophorus cells

Triggering final follicular maturation: hCG, GnRH-agonist, or both, when and to whom?

The dilemma of counseling patients about poor prognosis: live birth after IVF with autologous oocytes in a 43-year-old woman with FSH levels above 30 mIU/mL

Cumulative live birth and surplus embryo incidence after frozen-thaw cycles in PCOS: how many oocytes do we need?

Complete protection against cryodamage of cryopreserved whole bovine and human ovaries using DMSO as a cryoprotectant

The benefits of dual and double ovulatory triggers in assisted reproduction